Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/57560
Full metadata record
DC FieldValueLanguage
dc.contributor.authorŞahbudak Bal, Zümrüt-
dc.contributor.authorArslan, Sema Yıldırım-
dc.contributor.authorGüner Özenen, Gizem-
dc.contributor.authorOkur, Dicle Şener-
dc.contributor.authorKılıçaslan, Önder-
dc.contributor.authorDemirbuğa, Asuman-
dc.contributor.authorTurgut, Elif Afat-
dc.contributor.authorDalgic, Nazan-
dc.contributor.authorBelet, Nursen-
dc.contributor.authorInceli, Hatice Belkis-
dc.contributor.authorElvan-Tuz, Aysegul-
dc.contributor.authorKara, Tugce Tural-
dc.contributor.authorBulbul, Beyhan-
dc.contributor.authorDemirdag, Tugba-
dc.contributor.authorCakici, Ozlem-
dc.contributor.authorBal, Alkan-
dc.contributor.authorErgun, Deniz-
dc.contributor.authorAltug, Umut-
dc.contributor.authorArslan, Asli-
dc.contributor.authorIsancli, Didem Kizmaz-
dc.contributor.authorTorun, Selda Hancerli-
dc.contributor.authorCelik, Umit-
dc.contributor.authorYasar, Belma-
dc.contributor.authorErbas, Irem Ceren-
dc.contributor.authorOncel, Eda Karadag-
dc.contributor.authorAkbas, Ali-
dc.contributor.authorGudeloglu, Elif-
dc.contributor.authorSen, Semra-
dc.contributor.authorKacar, Pelin-
dc.contributor.authorDede, Elif-
dc.contributor.authorPetmezci, Ercument-
dc.contributor.authorAksoy, Fatma Dilsad-
dc.contributor.authorKarbuz, Adem-
dc.contributor.authorOncel, Selim-
dc.contributor.authorTezer, Hasan-
dc.contributor.authorDevrim, Ilker-
dc.contributor.authorCiftci, Ergin-
dc.contributor.authorHacimustafaoglu, Mustafa-
dc.contributor.authorKurugol, Zafer-
dc.date.accessioned2024-07-28T17:16:00Z-
dc.date.available2024-07-28T17:16:00Z-
dc.date.issued2024-
dc.identifier.issn2168-8184-
dc.identifier.urihttps://doi.org/10.7759/cureus.60940-
dc.identifier.urihttps://hdl.handle.net/11499/57560-
dc.description.abstractBackground Vaccines have the most important role in the battle against the COVID-19 pandemic. With the widespread use of vaccines, COVID-19 has remarkably declined. Adolescents were vaccinated after approvals for this age group, which was later than adults, and a nationwide vaccination program was implemented in August 2021 in Turkey for adolescents >= 12 years of age. Therefore, we aimed to determine the effects of the COVID-19 nationwide adolescent vaccination program on adolescent hospitalizations due to COVID-19 and multisystem inflammatory syndrome in children (MIS-C) by comparing two periods, including the vaccination period (VP) and the pre-VP (PVP). The second aim of this study is to compare the clinical features and disease severity of vaccine-breakthrough COVID-19 hospitalizations with unvaccinated individuals in the VP. Methods A retrospective multicenter study was conducted to determine and compare the number of hospitalizations due to COVID-19 and MIS-C between the VP (September 1, 2021, to August 31, 2022) and PVP (September 1, 2020, to August 31, 2021). We also compared the characteristics, risk factors, and outcomes of breakthrough infections of adolescents aged 12-18, which required hospitalization with the same age group of unvaccinated hospitalized individuals during the VP. Results During the study period, 3967 children (0-18 years) were hospitalized in the PVP and 5143 (0-18 years) in the VP. Of them, 35.4% were adolescents (12-18 years) in the PVP, and this rate was 18.6% in the VP; relative risk was 0.6467 (95% confidence interval [CI]: 0.6058-0.6904; p < 0.001). Patients with breakthrough COVID- 19 were older (201 vs. 175 months, p < 0.001) and less commonly hospitalized for COVID-19 (81.5% vs. 60.4%, p < 0.001, odds ratio [OR]: 0.347 [95% CI: 0.184-0.654]). The majority of these infections were asymptomatic and mild (32% vs.72.9%: p < 0.001, OR: 5.718 [95% CI: 2.920-11.200]), and PICU admission was less frequently required (p = 0.011, OR: 0.188 [95% CI: 0.045-0.793]). Most breakthrough COVID-19 infections occurred within three months after the last vaccine dose (54.2%). Conclusions This study demonstrated a significant decrease in adolescent hospitalizations due to COVID-19 and MIS -C after implementing COVID-19 vaccines in Turkey. Breakthrough cases were less severe and mostly occurred three months after the last dose. This study emphasizes the importance of COVID-19 vaccines and that parents' decisions may be changed, particularly those who hesitate to or refuse vaccination.en_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofCureus Journal of Medical Scienceen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjecthospitalization in covid-19en_US
dc.subjectadolescenten_US
dc.subjectcovid-19en_US
dc.subjectsars-cov-2en_US
dc.subjectvaccine breakthrough infectionen_US
dc.subjectSars-Cov-2 Infectionen_US
dc.titleAdolescents With Breakthrough COVID-19 Infections Requiring Hospitalization: A Multicenter Retrospective Studyen_US
dc.typeArticleen_US
dc.identifier.volume16en_US
dc.identifier.issue5en_US
dc.departmentPamukkale Universityen_US
dc.identifier.doi10.7759/cureus.60940-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid38915988en_US
dc.identifier.wosWOS:001250408900028en_US
dc.institutionauthor-
item.cerifentitytypePublications-
item.languageiso639-1en-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextWith Fulltext-
item.openairetypeArticle-
crisitem.author.dept14.02. Internal Medicine-
crisitem.author.dept14.02. Internal Medicine-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
cureus-0016-00000060940.pdf286.41 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

Page view(s)

24
checked on Aug 24, 2024

Download(s)

2
checked on Aug 24, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.